EUROPEAN
COMMISSION

Brussels, 23.8.2018
C(2018)5718 (final)

COMMISSION IMPLEMENTING DECISION

of 23.8.2018

granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Yescarta - axicabtagene ciloleucel", an orphan medicinal product for human use

(Text with EEA relevance)

(ONLY THE DUTCH TEXT IS AUTHENTIC)

COMMISSION IMPLEMENTING DECISION

of 23.8.2018

granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Yescarta - axicabtagene ciloleucel", an orphan medicinal product for human use

(Text with EEA relevance)

(ONLY THE DUTCH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[1], and in particular Article 10(2) thereof,

Having regard to Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products[2], and in particular Article 5(12) thereof,

Having regard to Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004[3],

Having regard to the application submitted by Kite Pharma EU B.V., on 17 August 2017, under Article 4(1) of Regulation (EC) No 726/2004,

Having regard to the opinions of the European Medicines Agency, formulated on 28 June 2018 by the Committee for Medicinal Products for Human Use and on 19 July 2018 by the Committee for Orphan Medicinal Products,

Whereas:

(1) Commission Decisions C(2014)10041(final) and C(2015)7024(final), adopted in accordance with Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products designated "Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor" as an orphan medicinal product.

(2) The medicinal product "Yescarta - axicabtagene ciloleucel" complies with the requirements set out in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use[4] and in Regulation (EC) No 1394/2007.

[1] OJ L 136, 30.4.2004, p. 1.
[2] OJ L 18, 22.1.2000, p. 1.
[3] OJ L 324, 10.12.2007, p. 121.

(3) It is therefore appropriate to authorise its placing on the market.

(4) The Committee for Medicinal Products for Human Use considered that "axicabtagene ciloleucel" is a new active substance.

(5) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,

HAS ADOPTED THIS DECISION:

Article 1

The marketing authorisation provided for in Article 3 of Regulation (EC) No 726/2004 is granted for the orphan medicinal product "Yescarta - axicabtagene ciloleucel", the characteristics of which are summarised in Annex I to this Decision. "Yescarta - axicabtagene ciloleucel" shall be registered in the Community register of medicinal products under number EU/1/18/1299.

Article 2

The marketing authorisation concerning the medicinal product referred to in Article 1 shall be subject to compliance with the conditions set out in Annex II and, in particular, with those relating to manufacture and importation, control and issue.

Article 3

The labelling and package leaflet concerning the orphan medicinal product referred to in Article 1 shall conform to Annex III.

Article 4

The period of validity of the authorisation shall be five years from the date of notification of this Decision.

Article 5

This Decision is addressed to Kite Pharma EU B.V., Science Park 408, 1098 XH Amsterdam, Nederland.

Done at Brussels, 23.8.2018

For the Commission

Xavier PRATS MONNÉ
Director-General

[4] OJ L 311, 28.11.2001, p. 67.